​

Relmada Therapeutics (RLMD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

RLMD Stock Forecast

Relmada Therapeutics stock forecast is as follows: an average price target of $5.67 (represents a 1467.60% upside from RLMD’s last price of $0.36) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

RLMD Price Target

The average price target for Relmada Therapeutics (RLMD) is $5.67 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $2.00. This represents a potential 1467.60% upside from RLMD's last price of $0.36.

RLMD Analyst Ratings

Buy

According to 2 Wall Street analysts, Relmada Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RLMD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).

Relmada Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 05, 2024Andrea TanGoldman Sachs$2.00$2.95-32.20%452.94%
Oct 13, 2022Andrew TsaiJefferies$8.00$6.4723.55%2111.78%
Oct 13, 2022Jay OlsonOppenheimer$7.00$6.753.73%1835.31%

The latest Relmada Therapeutics stock forecast, released on Jun 05, 2024 by Andrea Tan from Goldman Sachs, set a price target of $2.00, which represents a -32.20% decrease from the stock price at the time of the forecast ($2.95), and a 452.94% increase from RLMD last price ($0.36).

Relmada Therapeutics Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$2.00
Last Closing Price$0.36$0.36$0.36
Upside/Downside-100.00%-100.00%452.94%

In the current month, the average price target of Relmada Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Relmada Therapeutics's last price of $0.36. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024JefferiesBuyUpgrade
Jun 05, 2024Goldman SachsSellDowngrade
Oct 13, 2022OppenheimerPerformDowngrade

Relmada Therapeutics's last stock rating was published by Jefferies on Sep 16, 2024. The company Upgrade its RLMD rating from "null" to "Buy".

Relmada Therapeutics Financial Forecast

Relmada Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Relmada Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RLMD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Relmada Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict RLMD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Relmada Therapeutics's previous annual EBITDA (undefined) of $NaN.

Relmada Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-1.81M$-3.47M$-7.54M$-9.35M$-21.32M$-20.37M$-24.97M
High Forecast$-1.81M$-3.47M$-7.54M$-3.02M$-19.80M$-20.37M$-24.97M
Low Forecast$-1.81M$-3.47M$-7.54M$-15.69M$-22.85M$-20.37M$-24.97M
Surprise %-------

Relmada Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RLMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Relmada Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Relmada Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to RLMD last annual SG&A of $NaN (undefined).

Relmada Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.06$-0.12$-0.25$-0.31$-0.71$-0.68$-0.83
High Forecast$-0.06$-0.12$-0.25$-0.10$-0.66$-0.68$-0.83
Low Forecast$-0.06$-0.12$-0.25$-0.52$-0.76$-0.68$-0.83
Surprise %-------

According to undefined Wall Street analysts, Relmada Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RLMD previous annual EPS of $NaN (undefined).

Relmada Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
RLMDRelmada Therapeutics$0.36$5.671475.00%Buy
STTKShattuck Labs$1.15$12.00943.48%Hold
IPSCCentury Therapeutics$1.17$5.00327.35%Buy
PMVPPMV Pharmaceuticals$1.52$6.00294.74%Buy
BCYCBicycle Therapeutics$15.14$43.67188.44%Buy
NUVBNuvation Bio$2.81$7.00149.11%Buy
RAPTRAPT Therapeutics$0.84$2.00138.10%Hold
CYTKCytokinetics$47.78$90.0088.36%Buy
DYNDyne Therapeutics$26.16$49.0087.31%Buy
THRDThird Harmonic Bio$11.35$20.0076.21%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
NAMSNewAmsterdam Pharma Company$26.61$39.3347.80%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy

RLMD Forecast FAQ

Is Relmada Therapeutics a good buy?

Yes, according to 2 Wall Street analysts, Relmada Therapeutics (RLMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of RLMD's total ratings.

What is RLMD's price target?

Relmada Therapeutics (RLMD) average price target is $5.67 with a range of $2 to $8, implying a 1467.60% from its last price of $0.362. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Relmada Therapeutics stock go up soon?

According to Wall Street analysts' prediction for RLMD stock, the company can go up by 1467.60% (from the last price of $0.362 to the average price target of $5.67), up by 2111.78% based on the highest stock price target, and up by 452.94% based on the lowest stock price target.

Can Relmada Therapeutics stock reach $1?

RLMD's average twelve months analyst stock price target of $5.67 supports the claim that Relmada Therapeutics can reach $1 in the near future.

What are Relmada Therapeutics's analysts' financial forecasts?

Relmada Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-66.66M (high $-65.137M, low $-68.183M), average SG&A $0 (high $0, low $0), and average EPS is $-2.209 (high $-2.159, low $-2.26). RLMD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-22.178M (high $-15.841M, low $-28.515M), average SG&A $0 (high $0, low $0), and average EPS is $-0.735 (high $-0.525, low $-0.945).